How to Appeal a GLP-1 Denial

A denial is not a final answer, but it is a fork in the road, and which branch you are on decides everything you do next. The first job is not to write an angry letter. It is to read the letter you received and figure out what kind of “no” it is.

This guide explains the process and your rights. It does not give medical advice, and it will not tell you what to say about your own health — that is your prescriber’s role. Where it describes how a medicine is used, it is summarizing FDA-approved labeling and Instructions for Use; follow your own prescription and your prescriber’s directions.

What kind of denial is this?

There are two fundamentally different kinds, and they have different odds.

A plan exclusion means your employer or insurer decided not to cover drugs used for weight loss at all. There is no benefit to argue about. In February 2026, a federal appeals court affirmed dismissal of a class action alleging that a plan’s weight-loss drug exclusion amounted to disability discrimination, holding that the complaint had not plausibly alleged the plaintiff’s obesity substantially limits a major life activity [14]. No federal court has held these exclusions unlawful. Appealing an exclusion on medical grounds almost never works.

A medical necessity or criteria denial means the plan does cover the category, but concluded this particular request did not meet its written rules. These are the appealable denials, and the data says they are worth appealing.

The denial letter tells you which you have, because federal rules require it to reference the specific plan provisions it relies on [1]. A letter that cites a plan exclusion for weight-loss drugs is an exclusion. A letter that says you did not meet a BMI threshold, did not document a lifestyle program, or did not try a required first-line drug is a criteria denial.

What do the numbers say about my odds?

Denials are common and appeals are rare. KFF’s August 2026 analysis of the prior authorization metrics insurers were first required to publish for calendar year 2025 found average denial rates of 12 percent of standard prior authorization requests in Medicare Advantage, 14 percent in Medicaid managed care and 18 percent in ACA federally facilitated Marketplace plans [7]. When those denials are appealed, a large share are reversed: 67 percent in Medicare Advantage, 47 percent in Medicaid managed care and 43 percent in the ACA Marketplace [7].

Read one limitation into every one of those numbers before you use them: the CMS reporting rule those metrics come from requires payers to aggregate all medical items and services excluding prescription drugs. So they describe how these insurers handle prior authorization in general, and say nothing directly about a pharmacy-benefit GLP-1 request.

A separate KFF analysis of 2024 CMS data found Medicare Advantage insurers made nearly 53 million prior authorization determinations, denied 4.1 million of them, and that just 11.5 percent of those denials were appealed — while 80.7 percent of the appeals that were filed overturned the denial [8].

Two caveats. These figures cover medical items and services rather than drugs — the transparency rule excludes prescription drugs outright, and no public dataset breaks out weight-management drug appeals at all. And the high overturn rates almost certainly reflect criteria denials being fixed with better documentation, not exclusions being reversed. Still, the pattern they describe is consistent across every market measured: most people give up, and most people who do not give up win.

What does my denial letter have to tell me?

Under the federal claims rules that govern group health plans and non-grandfathered individual policies, an adverse benefit determination must include [1][2]:

• the specific reason or reasons for the denial;
• reference to the specific plan provisions on which it is based;
• a description of any additional material or information needed to perfect the claim, and why it is needed;
• a statement that you are entitled, free of charge, to receive documents relevant to your claim;
• a description of the plan’s review procedures and the time limits that apply, including your right to bring a civil action under ERISA section 502(a);
• if the denial is based on medical necessity, an experimental exclusion or a similar limit, an explanation of the scientific or clinical judgment applied to your circumstances — or a statement that this explanation will be provided free on request; and
• either the internal rule, guideline, protocol or criterion relied on, or a statement that no such criterion exists.

If your letter does not name the criterion it applied, that is a defect worth pointing out, and worth fixing by request. A first request in writing costs you nothing and often produces the exact checklist your prescriber needs.

What are the first three things I should do?

One: request your claim file and the criteria. Write to the plan and ask for a free copy of the complete claim file, the clinical criteria applied to your request, and any internal guidelines relied on. You have this right under the claims rules [1]. Note the date you asked.

Two: calendar the deadline. Federal rules give claimants at least 180 days to file an internal appeal after an adverse benefit determination [1]. Medicare drug plans differ: Medicare.gov says a Level 1 redetermination must be requested within 65 days of the date on the initial denial notice, then 60 days at each level after [5]. Put the date in your calendar and work backward.

Three: ask your prescriber’s office to look at the criteria with you. Most denials are fixed by documentation, not argument. Provider-facing guidance recommends attaching the chart note, weight history, labs and a brief letter of medical necessity with the submission rather than waiting for the plan’s request for additional information, which adds weeks [12].

What goes into a letter of medical necessity?

Your prescriber writes and signs this; you cannot. But knowing what a complete one contains helps you make sure nothing is missing. Guides for clinicians converge on the same elements [12]:

• your name, date of birth, member ID and plan name;
• the exact drug, strength, and the duration being requested;
• the diagnosis with ICD-10 codes and a BMI code;
• baseline and current weight and BMI, each with a measurement date;
• documented weight-related conditions;
• a history of prior interventions — programs, drugs, dates, outcomes and why anything stopped;
• relevant labs;
• a point-by-point statement mapping your situation to each criterion in the plan’s own published policy; and
• the prescriber’s NPI and signature.

The single most effective structural choice is that last point: write the letter in the order the plan’s policy is written, criterion by criterion, so a reviewer can tick each box without hunting. Practice guides recommend keeping it to two pages with the records attached.

How do the appeal levels work for commercial insurance?

Internal appeal. Group health plans may require up to two levels of internal appeal. An individual-market issuer must provide only one level before issuing a final determination [2]. Urgent-care claims must be decided as soon as possible and no later than 72 hours [1]. If a plan fails to follow the rules strictly, you are deemed to have exhausted the internal process and may go straight to court under ERISA section 502(a), with a court reviewing the claim fresh rather than deferring to the plan [1].

Peer-to-peer review. Alongside or instead of a written appeal, your prescriber can request a conversation with a clinician working for the plan. The NAIC reports that 26 jurisdictions have provisions addressing peer-to-peer appeal processes, most commonly requiring the plan’s reviewer be of the same or a similar specialty as the requesting provider [11]. It is often faster than paper. Only the prescriber can ask.

External review. This is the step people most often miss, and it is where independent eyes finally see the file. The Affordable Care Act gives you the right to have a final denial reviewed by an outside reviewer whose decision the insurer must accept. You must request it within four months of receiving the final internal denial. The plan completes a preliminary eligibility review within five business days. Standard external reviews are decided no later than 45 days after the request is received; expedited reviews no later than 72 hours [3][4].

Which external review process applies depends on your plan. Most states run their own. Plans in states without a qualifying process, and self-funded non-federal governmental plans, use the HHS-administered Federal External Review Process operated by MAXIMUS Federal Services, which accepts requests through a secure online portal, by fax at 1-888-866-6190, by mail, or by email at ferp@maximus.com; the request line is 1-888-866-6205 [3][4]. Self-funded private employer plans use a plan-selected independent review organization under the federal rules. Your final denial letter must tell you which applies and give you the contact information.

Some state processes are unusually accessible. California runs an Independent Medical Review program — through the Department of Managed Health Care for HMO and most PPO enrollees, and the Department of Insurance for policies it regulates — that is free to the consumer and binding on the insurer [9]. Pennsylvania accepts independent external review requests entirely online and offers an expedited track when life or health is at serious risk, with a physician certification form [10].

Who can help me for free?

• State Consumer Assistance Programs and Departments of Insurance. HealthCare.gov points consumers to them specifically for help filing internal appeals and external reviews [3].
• A state health insurance ombudsman, where one exists, is independent of the insurer and free to use.
• Your State Health Insurance Assistance Program (SHIP) for Medicare questions.
• Your prescriber’s prior authorization staff, who deal with these criteria daily.

How do Medicare appeals work?

Medicare drug coverage has five levels, and a coverage determination request comes before all of them [5][6]:

1. Coverage determination or exception request. Your prescriber submits a supporting statement. Once the plan has it, the plan must give written notice within 24 hours for an expedited request or 72 hours for a standard one, and may give verbal notice if written follow-up is mailed within 3 calendar days [6]. If the plan misses the deadline, the request is automatically forwarded to the independent review entity.
2. Level 1 — redetermination by the plan. File within 65 days of the denial notice date. Decisions: 7 days for a standard benefit request, 14 days for a payment request, 72 hours for a fast appeal [5].
3. Level 2 — reconsideration by an independent review entity. File within 60 days. Same clocks.
4. Level 3 — hearing before an administrative law judge at the Office of Medicare Hearings and Appeals. File within 60 days. A minimum dollar amount in controversy applies and is adjusted annually. For calendar year 2026 it is $200 (verified 2026-09-14), set by the CMS annual adjustment notice published in the Federal Register on December 4, 2025 and repeated on CMS’s own third-level-appeal page; it was $190 in 2025 and $180 in 2024. Claims can be combined to meet it.
5. Level 4 — Medicare Appeals Council review (60 days to file, same $200 threshold), then Level 5 — federal district court (60 days to file), which has a higher dollar threshold: $1,960 for calendar year 2026, up from $1,900 in 2025 and $1,840 in 2024 [5][15][16]. Some consumer pages on Medicare.gov still displayed the older 2024 examples when checked on September 14, 2026; the Federal Register notice and the CMS appeals pages carry the current figures.

Two Medicare-specific notes for GLP-1 patients. First, an exception request is the right tool when the drug is not on the formulary or when you want a restriction like a quantity limit or step therapy lifted; a tiering exception is a different request that asks only for a lower copay [6]. Second, the Medicare GLP-1 Bridge demonstration has no appeals process at all. If a Bridge prior authorization is denied, CMS says the prescriber may resubmit the form with corrected, updated or additional information [13].

What if my renewal was denied after the drug worked?

This is one of the most common and most fixable GLP-1 denials. Plans that gate initial approval on a high BMI can deny a renewal because successful treatment moved you below the threshold. Several policies address it directly — Evernorth tells providers that for a patient already on a GLP-1, the baseline BMI at the initial coverage review is the BMI used for coverage, and Aetna’s Zepbound policy instructs reviewers to consider the weight-related comorbidity present at the start of any drug therapy for patients transitioning from another weight-loss drug.

The other common renewal failure is a documentation mismatch: the plan wants the baseline weight recorded at the original authorization and the office submits the most recent visit weight. Ask that both be included, each with its date.

A realistic plan of attack

1. Read the letter. Identify exclusion versus criteria denial.
2. Request the claim file and the applied criteria in writing.
3. Calendar every deadline the letter gives you.
4. Meet with your prescriber’s office and go through the criteria line by line.
5. Submit a complete internal appeal with records attached, not a bare letter.
6. Ask your prescriber about a peer-to-peer review if the plan offers one.
7. If the internal appeal fails, file for external review within four months.
8. If you get stuck, call your state Consumer Assistance Program or Department of Insurance.

And keep everything: dates, names, reference numbers, fax confirmations, copies of every page you sent. If your case reaches an outside reviewer, your paper trail is the case.

Sources

1. 29 CFR 2560.503-1, Claims procedure, Cornell Legal Information Institute. https://www.law.cornell.edu/cfr/text/29/2560.503-1
2. 45 CFR 147.136, Internal claims and appeals and external review processes, eCFR. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-B/part-147/section-147.136
3. HealthCare.gov, External Review. https://www.healthcare.gov/appeal-insurance-company-decision/external-review
4. CMS / CCIIO, HHS-Administered Federal External Review Process for Health Insurance Coverage. https://www.cms.gov/cciio/programs-and-initiatives/consumer-support-and-information/csg-ext-appeals-facts
5. Medicare.gov, Appeals in a Medicare drug plan. https://www.medicare.gov/providers-services/claims-appeals-complaints/appeals/drug-plans
6. Centers for Medicare & Medicaid Services, Exceptions. https://www.cms.gov/medicare/appeals-grievances/prescription-drug/exceptions
7. KFF, Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain. https://www.kff.org/patient-consumer-protections/prior-authorization-metrics-provide-new-insights-into-insurer-practices-but-gaps-remain
8. KFF, Medicare Advantage Insurers Made Nearly 53 Million Prior Authorization Determinations in 2024. https://www.kff.org/medicare/medicare-advantage-insurers-made-nearly-53-million-prior-authorization-determinations-in-2024
9. California Department of Insurance, Independent Medical Review Program (IMR). https://www.insurance.ca.gov/01-consumers/101-help/Independent-Medical-Review-Program.cfm
10. Pennsylvania Insurance Department, Request a Review If Your Health Insurance Denied a Treatment, Medication, or Service. https://www.pa.gov/services/insurance/request-a-review-if-your-health-insurance-denied-a-treatment-medication-or-service
11. National Association of Insurance Commissioners, Prior Authorization White Paper, adopted December 10, 2025. https://content.naic.org/sites/default/files/inline-files/PA%20white%20paper%20Adopted%2012.10.2025%20by%20Cmte.pdf
12. Informed Plate, Prior Authorization for GLP-1 Obesity Medications: A Provider’s Guide. https://informedplate.com/glp1/prior-auth-guide
13. Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge — Information for Providers. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
14. Becker’s Payer Issues, Cigna defeats class action alleging GLP-1 coverage exclusions are disability discrimination. https://www.beckerspayer.com/legal/cigna-defeats-class-action-alleging-glp-1-coverage-exclusions-are-disability-discrimination
15. Centers for Medicare & Medicaid Services, Medicare Program; Medicare Appeals; Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2026, Federal Register, December 4, 2025. https://www.federalregister.gov/documents/2025/12/04/2025-21879/medicare-program-medicare-appeals-adjustment-to-the-amount-in-controversy-threshold-amounts-for
16. Centers for Medicare & Medicaid Services, Third Level of Appeal: Decision by the Office of Medicare Hearings and Appeals (OMHA). https://www.cms.gov/medicare/appeals-grievances/fee-for-service/third-level-appeal